I’ve re-entered into a position with Seelos Therapeutics ($SEEL). I’ve been waiting for an offering to happen and one finally did on Friday:). It dropped 28%, which in my opinion is an over reaction due to the offering and allows for a great entry point. Here’s some DD on $SEEL.

A $7 M direct offering was made at 0.79 with warrants exercisable at 0.84. $SEEL dipped to 0.59 on Friday.
Seelos Therapeutics has many drugs in its pipeline that are capable of bringing in a hefty revenue.

It includes SLS-002 an intranasal racemic ketamine nasal program for the treatment of Acute Suicidal ideation and behaviour (ASIB) in patients with Major Depressive Disorder. This has me thinking possible federal funding... think Veterans suicide...

The FDA has granted SLA-002 a fast track designation status. What does that mean? It means working in close collaboration with the FDA to expedite the approval of the drug for market usage. Fast tracked drugs often go to Market after phase 2.

SLS-005 has been granted Orphan Drug Designation in the US and Europe for Sanfilippo syndrome, Spinocerebellar Ataxia Type 3 (SCA3) and Oculopharyngeal Muscular Dystrophy (OPMD) as well as Fast Track designation for OPMD.
What does orphan drug designation status mean?

As investors this is what’s really important about an orphan drug status... orphan drug companies are comparatively valued at a 10-15% higher market value.

Seelos has also been awarded a priority review voucher upon approval of SLS-005 which has a fair transferable market value of $95-$250 million.